PARP1 and ischemic stroke: PARP inhibitors attenuate renal, cardiac, and intestinal ischemia‐reperfusion injuries.[47, 48, 49] A new PARP inhibitor, JPI‐289, has entered clinical trials in ischemic stroke patients; preclinical data confirmed its efficacy in reducing infarct size and alleviating inflammation.[50] However, the application of PARP inhibitors in inflammatory diseases is primarily limited to animal experiments.